Loading...

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541.HKHKSE
Healthcare
Biotechnology
HK$14.32
HK$-0.74(-4.91%)

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 1541.HK Peers

See (1541.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1541.HKHK$14.32-4.91%5.7B-15.57-HK$0.92N/A
1801.HKHK$79.95-1.42%132B-1142.14-HK$0.07N/A
2269.HKHK$26.65+0.38%108.4B31.35HK$0.85N/A
1177.HKHK$4.77N/A85.3B43.36HK$0.11+0.53%
9926.HKHK$94.15-2.28%84.4B-144.85-HK$0.65N/A
1530.HKHK$23.00-4.17%54.2B24.73HK$0.93+1.07%
3759.HKHK$16.72+0.36%43.8B14.54HK$1.15+1.51%
1877.HKHK$25.50+3.66%38.6B-17.96-HK$1.42N/A
1548.HKHK$16.86+0.36%36.3B-26.34-HK$0.64N/A
9688.HKHK$31.80+3.08%34.9B-16.22-HK$1.96N/A
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1541.HK vs 1801.HK Comparison

1541.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1541.HK stands at 5.7B. In comparison, 1801.HK has a market cap of 132B. Regarding current trading prices, 1541.HK is priced at HK$14.32, while 1801.HK trades at HK$79.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1541.HK currently has a P/E ratio of -15.57, whereas 1801.HK's P/E ratio is -1142.14. In terms of profitability, 1541.HK's ROE is -0.49%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 1541.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1541.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions